Fredun Pharmaceuticals Share Price

Fredun Pharmaceuticals' board has recommended a 2:1 bonus issue, granting two new equity shares for every one held. This decision aims to reward shareholders, reflecting management's confidence in the company's sustained earnings growth, scalability, and long-term value creation strategy.

• दी इकॉनॉमिक टाइम्स
• 3 आठवडे 4 दिवसांपूर्वी

The board declared a dividend of 0.70 per share and approved a bonus share issue in the ratio of 2:1

• बिझनेस लाईन
• 3 आठवडे 5 दिवसांपूर्वी

Pharmaceuticals company Fredun Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations: Consolidated revenue for Q4FY26 reached Rs 21,041.20 lakh, a YoY increase of 27.18% from Rs 16,543.78 Q4FY25 मध्ये लाख आणि QoQ मध्ये ₹15,992.63 पासून 31.57% वाढ लाख Q3FY26 मध्ये. एकूण इन्कम: Q4FY26 साठी एकत्रित एकूण इन्कम ₹21,305.51 होते लाख, ₹16,740.74 पासून 27.27% YoY पर्यंत लाख आणि 32.40% QoQ पर्यंत ₹ 16,092.33 पासून लाख Q3FY26 मध्ये. टॅक्सपूर्व नफा (PBT): Q4FY26 साठी एकत्रित PBT ₹ 1,124.81 होता lakh, showing a YoY growth of 54.84% from Rs 726.44 lakh, but declining 19.67% QoQ रु. 1,400.24 पासून लाख Q3FY26 मध्ये. निव्वळ नफा: Q4FY26 साठी निव्वळ नफा ₹1,078.00 होता lakh, representing a 79.56% YoY increase from Rs 600.35 lakh and a 2.88% QoQ increase from Rs 1,047.80 lakh in Q3FY26. Full Year Performance: Consolidated revenue for FY26 was Rs 63,332.65 lakh, up 40.21% वार्षिक ₹ 45,170.65 लाख पासून. Annual consolidated net profit grew by 65.26% to Rs 3,262.09 आर्थिक वर्ष 25 मध्ये ₹1,973.93 लाखांच्या तुलनेत लाख. Standalone Financial Highlights: Revenue from operations: For Q4FY26, the company reported revenue of Rs 21,041.20 lakh, representing a growth of 27.18% YoY from Rs 16,543.76 lakh in Q4FY25 and an increase of 31.57% QoQ रु. 15,992.63 पासून लाख Q3FY26 मध्ये. Total Income: Total income for Q4FY26 was Rs 21,305.20 lakh, up by 27.27% YoY compared to Rs 16,740.72 lakh in Q4FY25 and a growth of 32.39% QoQ from Rs 16,092.33 लाख Q3FY26 मध्ये. Profit Before Tax (PBT): PBT for Q4FY26 stood at Rs 1,153.32 lakh, marking a 43.42% increase YoY from Rs 804.17 lakh, though it saw a QoQ decline of 17.64% from Rs 1,400.25 lakh in Q3FY26. निव्वळ नफा: कंपनीने ₹1,106.51 चा निव्वळ नफा नोंदवला lakh in Q4FY26, showing a growth of 56.47% YoY from Rs 707.18 lakh in Q4FY25 and an increase of 5.60% QoQ from Rs 1,047.81 लाख Q3FY26 मध्ये. Full Year Performance: For the full year FY26, revenue from operations reached Rs 63,332.65 lakh, representing a 40.21% increase from Rs 45,170.62 लाख आर्थिक वर्ष 25 मध्ये. Net profit for the year stood at Rs 3,320.69 lakh, up by 59.59% compared to Rs 2,080.76 लाख आर्थिक वर्ष 25 मध्ये. कमाई प्रति शेअर (EPS): Q4FY25 मध्ये ₹14.98 च्या तुलनेत Q4FY26 साठी बेसिक EPS ₹20.22 होते. For the full year FY26, basic EPS grew to Rs 68.01 from Rs 44.83 in FY25. Business Highlights: Dividend: The Board has recommended a final dividend of 7% (Rs 0.70 per equity share) for the financial year 2025-26, subject to shareholder approval. Bonus Issue: The Board has recommended the issuance of bonus shares in the ratio of 2:1, i.e., two bonus equity shares of face value Rs 10/- each for every one existing equity share held. The bonus shares will be issued out of securities premium, general reserves, or retained earnings as of March 31, 2026. Authorized Capital: The Board approved an increase in the company's authorized share capital from Rs 10 crore to Rs 50 crore. Segment Performance: The company's business activity falls within a single operating segment viz. "Pharmaceutical and Healthcare," hence no separate segment results are disclosed. ऑडिटर अपॉईंटमेंट: कंपनी ने मे. Nikhil Maniar & Associates as the Internal Auditor and M/s. Joshi Apte & Associates as the Cost Auditor for the financial year 2026-27. Consolidated Entities: The consolidated results include the financial performance of three subsidiaries: Fredun Retail Private Limited, One Pet Stop Private Limited, and Wagr Retail Private Limited Result PDF

• ट्रेंडलाईन
• 3 आठवडे 5 दिवसांपूर्वी